drugset
drugset / Trial / NCT00618319

An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

NCT00618319 ↗

Phase 2 Completed 20 enrolled Biogen
NaSingle-groupOpen-labelTreatment

Summary

This study will examine the effect of BIIB021 on GIST growth and metabolism.

Timeline

Start
2008-02
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB021 Small molecule — —

Indications

gastrointestinal stromal tumor